Chronic Fatigue Syndrome Trial, Recruiting NCT07400848 Sponsor: University of Bern Condition: Chronic Fatigue Syndrome
Back to Chronic Fatigue Syndrome

Chronic Fatigue Syndrome Trial, Recruiting

NCT07400848
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have a good enough understanding of German to fill in questionnaires and take part in study activities

For the PROGRESS part of the study (patients only):

  • You are able to give consent online using a coded (anonymous) sign-up process
  • You have reported ongoing symptoms that you believe started after receiving a COVID-19 vaccine
  • You are willing and able to take part in follow-up activities over 8 months

For the ENDOCLOT and REAL parts (patients):

  • You have received at least one COVID-19 vaccine
  • You developed new symptoms that have no other explanation within 14 days of a COVID-19 vaccination
  • Those symptoms have continued for at least 6 months after vaccination
  • You have been diagnosed with ME/CFS (a specific chronic illness) according to recognised medical criteria, including a symptom called post-exertional malaise (PEM) (confirm with trial site)

For the ENDOCLOT and REAL parts (healthy volunteers):

  • You have had a COVID-19 vaccine but have not experienced any lasting side effects
  • You are within 10 years of age and the same sex as a matched patient in the study

Who may not be able to join:

  • You have a serious cognitive (thinking/memory), physical, or mental health condition that would make it difficult to participate
  • You currently have an active cancer or are taking medication that suppresses the immune system
  • You are known to be pregnant at the time of joining the study
  • You have had a confirmed or suspected COVID-19 infection after vaccination, or around the time your symptoms started
  • You already had Long COVID symptoms before or alongside your vaccine-related symptoms
  • You had any infection — even a mild or symptom-free one — around the same time as your COVID-19 vaccination (confirm with trial site)
  • You have a pre-existing medical condition or take ongoing medication that could reasonably explain your symptoms (for example, a previous diagnosis of ME/CFS, POTS, fibromyalgia, certain nerve conditions, autoimmune diseases, or similar long-term conditions)
  • You regularly take high doses of anti-inflammatory medication long-term

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Mirko Schmidt, Prof. Dr., Institute of Sport Science, University of Bern, Switzerland

Phone: +41 79 342 67 30

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University of Bern
Registry
ClinicalTrials.gov
Start date
22 March 2026
Est. completion
30 June 2026

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Self-reported health status (EQ-VAS); Health-related quality of life (EQ-5D-5L index score); Reactive Hyperemia Index (lnRHI)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov